USPTO serial 99620962
LAKEFRONT BIOTHERAPEUTICS
Reviewed by CopyMark Law Group
Status 681
- Filing date
- Status date
- Registration date
- —
- Examiner
- GEISER, EMILY A
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with LAKEFRONT BIOTHERAPEUTICS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Alexandra MacKay
Alexandra MacKay Stites & Harbison PLLC401 Commerce StreetSuite 800Nashville, TN 37219Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical substances and preparations for human use for the treatment of bone cartilage and joint disease, inflammatory diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, cancer, hematological cancer, solid tumors, endocrine diseases, metabolic diseases, skin diseases, lung diseases, fibrotic diseases, cardiovascular diseases, pain, hepatitis B virus, kidney diseases, osteoporosis, osteoarthritis, rheumatoid arthritis, atopic dermatitis, idiopathic pulmonary fibrosis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, Sjogren's syndrome, lupus, uveitis, scleroderma, dermatomyositis, urticaria, non-alcoholic steatohepatitis, polycystic kidney disease, type 2 diabetes; biopharmaceutical substances and preparations for human use for the treatment of bone cartilage and joint disease, inflammatory diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, cancer, hematological cancer, solid tumors, endocrine diseases, metabolic diseases, skin diseases, lung diseases, fibrotic diseases, cardiovascular diseases, pain, hepatitis B virus, kidney diseases, osteoporosis, osteoarthritis, rheumatoid arthritis, atopic dermatitis, idiopathic pulmonary fibrosis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, Sjogren's syndrome, lupus, uveitis, scleroderma, dermatomyositis, urticaria, non-alcoholic steatohepatitis, polycystic kidney disease, type 2 diabetes | ACTIVE | — |
| 042 | Medical and scientific research services; industrial research in the field of pharmaceuticals; pharmaceutical and biopharmaceutical research and development services; scientific and medical research services in the nature of examining and testing of genes; pharmaceutical and biopharmaceutical drug development services featuring the examination and testing of pharmaceutical and biopharmaceutical semi-finished products for use in medicaments; pharmaceutical drug development services featuring the examination and testing of medicaments; product research and development in the field of test systems for pharmaceutical and biopharmaceutical products; database development services, namely, configuration and customization of computer databases containing information regarding medical, pharmaceutical and biopharmaceutical information; pharmaceutical drug development services | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 4, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Oct 7, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 6, 2026 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Oct 6, 2026 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Oct 6, 2026 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Oct 6, 2026 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Aug 28, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 28, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 28, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 26, 2026 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| May 28, 2026 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 28, 2026 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 28, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 27, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| May 21, 2026 | MDSM | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| May 21, 2026 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 28, 2026 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jan 28, 2026 | NWAP | NEW APPLICATION ENTERED | — |